You are here

  • Home
  • Archive
  • Volume 105, Issue 9
  • P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation

Article info

Article menu

Download PDFPDF

Abstracts from the Neonatal and Paediatric Pharmacists Conference November 2019
Sutton Coldfield, UK
P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation
Free

Authors

Citation

Yaqub F, Crook J, Fell J
P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation
Archives of Disease in Childhood 2020;105:e37-e38.

Publication history

  • First published August 19, 2020.
Online issue publication 
February 11, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.